APERTO CVS PMCF Study

Inclusion Criteria: * Patients age \>18, no pregnant women, able to perform fup visits, life expectancy \> 12 months * Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic stenosis (de novo or restenosis) of the central veins with significant (\>50%) stenosis and diameter * The target lesion consists of one or more lesions with a target lesion length of less than or equal to 100 mm * The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in angiographic or ultrasound evaluation); * If there are other non-target lesions, then non-target lesions must be successfully cured with a not drug coated balloon before treating the target lesion; Exclusion Criteria: * Patients with CVS observed and estimated as nonsignificant (\< 50% stenosis) or a vessel \> 12 mm in diameter by visual estimation; * the patient is now participating in another clinical trial to evaluate drug or medical device; * patient enrolled for this trial before; * prenatal pregnancy test result for women of childbearing potential is non-negative, Lactating woman; * patients, who underwent major surgical procedures (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study; * patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within 30 days after enrolment; * central veins lesions have been already treated with DCB before * presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in central veins * patients allergic or intolerant to paclitaxel, or contrast media; * patients whose life expectancy is less than 1 year * presence of Thrombus in central veins * tumor compression * thoracic inlet syndrome * patients implanted with pacing or cardioverter devices with leads * any other central line within the target lesion * Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device